According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “
Other analysts have also recently issued reports about the company. ValuEngine cut Alpine Immune Sciences from a hold rating to a sell rating in a research note on Friday, January 11th. Oppenheimer set a $13.00 price target on Alpine Immune Sciences and gave the company a buy rating in a research note on Tuesday, March 19th. Finally, restated a buy rating and issued a $13.00 price target on shares of Alpine Immune Sciences in a research note on Tuesday, February 12th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $12.07.
Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.01). As a group, analysts anticipate that Alpine Immune Sciences will post -2.71 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc raised its stake in Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock valued at $1,442,000 after buying an additional 11,200 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Alpine Immune Sciences by 109.0% during the fourth quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 70,980 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Alpine Immune Sciences by 5.2% during the third quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 11,200 shares during the last quarter. Hikari Power Ltd purchased a new position in shares of Alpine Immune Sciences during the fourth quarter worth about $453,000. Finally, Raymond James & Associates purchased a new position in shares of Alpine Immune Sciences during the first quarter worth about $94,000. Institutional investors own 53.79% of the company’s stock.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Further Reading: Outstanding Shares and The Effect on Share Price
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.